AU2017236069B2 - Fusion proteins of PD-1 and 4-1BB - Google Patents

Fusion proteins of PD-1 and 4-1BB Download PDF

Info

Publication number
AU2017236069B2
AU2017236069B2 AU2017236069A AU2017236069A AU2017236069B2 AU 2017236069 B2 AU2017236069 B2 AU 2017236069B2 AU 2017236069 A AU2017236069 A AU 2017236069A AU 2017236069 A AU2017236069 A AU 2017236069A AU 2017236069 B2 AU2017236069 B2 AU 2017236069B2
Authority
AU
Australia
Prior art keywords
leu
ser
pro
fusion protein
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017236069A
Other languages
English (en)
Other versions
AU2017236069A1 (en
Inventor
Elfriede Noessner
Ramona SCHLENKER
Stephan WEISZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Zentrum München
Original Assignee
Helmholtz Zentrum München
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München filed Critical Helmholtz Zentrum München
Publication of AU2017236069A1 publication Critical patent/AU2017236069A1/en
Application granted granted Critical
Publication of AU2017236069B2 publication Critical patent/AU2017236069B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2017236069A 2016-03-23 2017-03-23 Fusion proteins of PD-1 and 4-1BB Active AU2017236069B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LU93006 2016-03-23
LULU93006 2016-03-23
PCT/EP2017/056931 WO2017162797A1 (en) 2016-03-23 2017-03-23 Fusion proteins of pd-1 and 4-1bb

Publications (2)

Publication Number Publication Date
AU2017236069A1 AU2017236069A1 (en) 2018-09-20
AU2017236069B2 true AU2017236069B2 (en) 2021-04-08

Family

ID=55702054

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017236069A Active AU2017236069B2 (en) 2016-03-23 2017-03-23 Fusion proteins of PD-1 and 4-1BB

Country Status (8)

Country Link
US (3) US11365237B2 (enExample)
EP (2) EP4286522A3 (enExample)
JP (2) JP7250519B2 (enExample)
CN (1) CN109195985B (enExample)
AU (1) AU2017236069B2 (enExample)
CA (1) CA3017036A1 (enExample)
ES (1) ES2962588T3 (enExample)
WO (1) WO2017162797A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3770168A1 (en) 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
PT3310805T (pt) 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
CN110177803A (zh) 2016-11-22 2019-08-27 T细胞受体治疗公司 用于使用融合蛋白进行tcr重新编程的组合物和方法
WO2018119198A1 (en) * 2016-12-22 2018-06-28 Windmil Therapeutics, Inc. Compositions and methods for modulating the immune system
WO2018181390A1 (ja) * 2017-03-31 2018-10-04 東亞合成株式会社 Ｐｄ－１シグナル配列を有する抗腫瘍ペプチドおよびその利用
IL280102B1 (en) * 2018-07-11 2026-07-01 Kahr Medical Ltd Fusion protein containing PD1-4-1BBL and methods of using the same
KR102351041B1 (ko) * 2018-12-19 2022-01-13 한국화학연구원 인간 lrrc24 단백질 유래 세포막 투과 도메인
CN113518823B (zh) * 2019-01-07 2025-05-02 托马斯杰斐逊大学 多功能的融合蛋白及其用途
EP3999079A4 (en) * 2019-07-19 2024-04-03 Memorial Sloan Kettering Cancer Center Fusion polypeptide for immunotherapy
EP4146701A4 (en) * 2020-05-06 2024-05-15 Navicure Biopharmaceuticals Limited Fusion proteins for immunotherapy against cancer and infectious diseases
WO2022036495A1 (en) * 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
US20230374104A1 (en) * 2020-10-09 2023-11-23 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods and compositions comprising pd1 chimeric polypeptides
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
CA3228669A1 (en) * 2021-08-10 2023-02-16 Ganesh Ramachandran Purification of liraglutide
WO2023025779A1 (en) * 2021-08-25 2023-03-02 Medigene Immunotherapies Gmbh Combination of antigen specific t cell receptors and chimeric co-stimulatory receptors
US20260055159A1 (en) * 2022-08-23 2026-02-26 Medigene Immunotherapies Gmbh Combination of ny-eso-1 specific t cell receptors and chimeric co-stimulatory receptors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019615A2 (en) * 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6074435B2 (ja) * 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
EP2970372B1 (en) * 2013-03-15 2020-09-30 Celgene Corporation Modified t lymphocytes
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
DK2992020T3 (da) 2013-05-03 2020-02-10 Ohio State Innovation Foundation Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller
EP3172231B1 (en) * 2014-07-24 2021-05-05 Bluebird Bio, Inc. Bcma chimeric antigen receptors
WO2016019300A1 (en) * 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
EP3250602A1 (en) * 2015-01-26 2017-12-06 Cellectis T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
AU2015380397B2 (en) * 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
BR112017018770A2 (pt) * 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
EP3770168A1 (en) * 2015-05-18 2021-01-27 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN104829733B (zh) * 2015-05-25 2018-06-05 广州百暨基因科技有限公司 抗原结合单元稳定的嵌合抗原受体及制备方法与应用
PT3310805T (pt) * 2015-06-19 2021-05-19 Kobold Sebastian Proteínas de fusão pd-1-cd28 e a sua utilização em medicina
MX2018000278A (es) * 2015-06-29 2018-03-08 Univ Johns Hopkins Terapia de receptores quimericos de puntos de control inmunitarios.
US11242375B2 (en) * 2015-09-04 2022-02-08 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
US20190241910A1 (en) * 2016-03-11 2019-08-08 Bluebird Bio, Inc. Genome edited immune effector cells
US11365237B2 (en) * 2016-03-23 2022-06-21 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Fusion proteins of PD-1 and 4-1BB
AU2019227979B2 (en) * 2018-03-02 2024-09-05 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
US12291557B2 (en) * 2018-03-28 2025-05-06 Cero Therapeutics Holdings, Inc. Chimeric TIM4 receptors and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019615A2 (en) * 2011-07-29 2013-02-07 The Trustees Of The University Of Pennsylvania Switch costimulatory receptors
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
WO2016141357A1 (en) * 2015-03-05 2016-09-09 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof

Also Published As

Publication number Publication date
JP2019512251A (ja) 2019-05-16
NZ745944A (en) 2025-05-30
JP2023078362A (ja) 2023-06-06
CA3017036A1 (en) 2017-09-28
CN109195985A (zh) 2019-01-11
CN109195985B (zh) 2022-07-26
US20190106478A1 (en) 2019-04-11
EP3433269A1 (en) 2019-01-30
EP3433269B1 (en) 2023-09-27
EP3433269C0 (en) 2023-09-27
US11365237B2 (en) 2022-06-21
AU2017236069A1 (en) 2018-09-20
EP4286522A3 (en) 2024-02-28
WO2017162797A1 (en) 2017-09-28
US12516101B2 (en) 2026-01-06
US20240247046A1 (en) 2024-07-25
EP4286522A2 (en) 2023-12-06
US20220380435A1 (en) 2022-12-01
ES2962588T3 (es) 2024-03-20
JP7250519B2 (ja) 2023-04-03
JP7746323B2 (ja) 2025-09-30

Similar Documents

Publication Publication Date Title
US12516101B2 (en) Fusion proteins of PD-1 and 4-1BB
JP7460675B2 (ja) Ｐｄ－１－ｃｄ２８融合タンパク質および医療におけるその使用
KR102957751B1 (ko) Mage a4 t 세포 수용체
RU2747733C1 (ru) Терапевтические средства
JP2021510063A (ja) Ｎｙｅｓｏ ｔｃｒ
KR20170120701A (ko) 면역조절 융합 단백질 및 그 용도
KR20210022690A (ko) 키메라 성장 인자 수용체
CN116615446A (zh) Mage-a3特异性t细胞受体及其用途
HK40109405A (en) Pd1-cd28 fusion proteins and their use in medicine
HK40064520A (en) Pd1-cd28 fusion proteins and their use in medicine
CN118525037A (zh) 识别ctnnb1中s37f突变的t细胞受体及其应用
EA048001B1 (ru) T-клеточные рецепторы, специфичные к mage-a4

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)